middle.news
How Is Immutep Advancing Its Lung Cancer Trial Amid Rising Losses?
4:02am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
How Is Immutep Advancing Its Lung Cancer Trial Amid Rising Losses?
4:02am on Saturday 30th of August, 2025 AEST
Key Points
FY2025 loss increased to A$61.4 million from A$42.7 million in FY2024
Lead candidate eftilagimod alfa (efti) entered global Phase III trial for non-small cell lung cancer
Strong cash balance of A$129.7 million ensures runway through end of 2026
Promising clinical data reported in head and neck cancer and autoimmune disease programs
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Immutep (ASX:IMM)
OPEN ARTICLE